Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering Graves’ orbitopathy: a case series

Alemtuzumab—a monoclonal antibody targeting the CD52 glycoprotein expressed by most mature leucocytes—effectively decreases relapse rate and disability progression in early, relapsing–remitting multiple sclerosis (MS). However, secondary autoimmune disorders complicate therapy in nearly 50% of treat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eye (Lond)
Autors principals: Roos, Jonathan C. P., Moran, Carla, Chatterjee, V. Krishna, Jones, Joanne, Coles, Alasdair, Murthy, Rachna
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2018
Matèries:
Conference Proceeding
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6367353/
https://ncbi.nlm.nih.gov/pubmed/30498266
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41433-018-0282-1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars